Generate:Biomedicines

Today, Samsung Biologics announced an investment through its Life Science Fund, highlighting confidence in our platform and team to advance therapeutic discovery with #GenerativeAI. This funding supports our efforts to design novel protein-based medicines and tackle some of the toughest challenges in human health. Samsung Biologics CEO John Rim emphasized the importance of leveraging innovation in #AI and #MachineLearning to build an ecosystem for next-generation therapeutic development, manufacturing, and R&D collaboration. With clinical programs already underway and plans to add three to six more in the next 18 months, we’re turning technological promise into tangible outcomes for patients. Learn more about Samsung’s investment: https://lnkd.in/ejv2X5CJ #ProgrammingBiology | #NowWeCan

“Whenever complex domains become engineerable, revolutions happen. We are at the start of one for biology,” shares Michael Nally, our CEO, on the latest episode of "Life Sciences DnA" (Levine Media Group) with host Amar Drawid, Ph.D. Mike describes how Generate:Biomedicines’ iterative approach—powered by a vast and growing base of proprietary data—continues to refine its ability to design and test proteins at unprecedented scale. “Every experiment builds on the last,” Mike explains, “adding to a knowledge base that makes tackling biology’s toughest challenges increasingly within reach.” Hear how technology, data, and biology are converging to reshape drug discovery: https://lnkd.in/ev8t-Phz #GenerativeAI | #ProgrammingBiology

NVIDIA’s journey is one of vision, innovation, and transformation. In "The Nvidia Way", writer and journalist Tae Kim explores how this groundbreaking company has shaped the future of #AI under the leadership of CEO Jensen Huang. Our Co-Founder and CTO, Gevorg Grigoryan, spoke with Kim about NVIDIA’s impact on the study of biomolecules, describing it as a “beautiful marriage between NVIDIA and molecular science.” He explains how NVIDIA’s tools and hardware have helped bring computation and molecular biology into closer harmony, enabling researchers to tackle questions once thought unimaginable. Explore the rise of #ArtificialIntelligence and NVIDIA’s central role in it: https://www.taekim.com #GenerativeAI | #ProgrammingBiology

Our Mindset Awards honor those who bring our values to life, driving progress, and inspiring innovation across everything we do. The final award of the year celebrates #RelentlessCuriosity — a mindset that fuels discovery and pushes boundaries. This year, we recognize Wujie Wang for his remarkable contributions in symmetric complexes, #ProteinDesign, and biophysically informed #MachineLearning. Wujie’s curiosity drives innovation, sparking collaboration, and advancing approaches that shape the future of our work. Curious about what it means to think differently? Explore careers here: https://lnkd.in/gKaKkEGJ #ProgrammingBiology | #GenerativeAI

In the Timmerman Report, Simon Barnett explores how #MachineLearning is revolutionizing therapeutic #ProteinDesign in his article, "Computational Techniques Are Driving a Tidal Shift in Therapeutic Protein Design." Barnett illustrates that this shift isn’t a distant prospect—it’s happening now. Computational approaches are redefining drug discovery by compressing timelines, enhancing precision, and enabling breakthroughs that traditional methods could not achieve. Barnett highlights how established and growing pharma companies are increasingly outsourcing biologics R&D to companies like Generate:Biomedicines, which he describes as an "exceptional platform company with burgeoning pipelines in therapeutic protein design." Machine learning is changing the game in biopharma. Read how: https://lnkd.in/exSwSrmr #GenerativeAI | #ProgrammingBiology

We’re thrilled to share that Chroma, our #GenerativeAI model, has won the "MSD Innovation Award" at the 2024 #ScripAwards (Citeline). This award honors breakthroughs with the potential to transform the discovery or development of new medicines. Chroma is designed to program novel proteins not previously found in nature, applying targeted biophysical, biological, and therapeutic properties to unlock new possibilities in drug discovery. Want to learn more? Explore Chroma and build your own protein structures here: https://lnkd.in/emxTeCJX #ProgrammingBiology | #UnapologeticallyScientific

Drug development is a $1.6 trillion industry, yet the process remains largely unchanged—until now. On December 12, our EVP of R&D, Alexandra Snyder, MD, joins Bloomberg Intelligence's AI & Drug Development Forum to discuss how #AI is accelerating preclinical development. Joining Alex are Andrew Pierce from Owkin and moderator A.H. Van Kirk from Bloomberg Intelligence. Together, they’ll explore how #GenerativeBiology is transforming #MolecularDesign, optimization, and testing in the panel, “Accelerating Preclinical Development with AI.” Don’t miss this opportunity: https://lnkd.in/eE2x9E8M  #GenerativeAI | #ProgrammingBiology

How is #GenerativeAI reshaping intellectual property strategies? On December 4, K. Nicole Clouse, our Head of Intellectual Property, will join the panel “IP and Generative AI: What’s Next?” at Consero's IP Forum for Life Sciences. Moderated by Shelley Danek from Marshall, Gerstein & Borun LLP, the panel will also feature Elbert Chiang from Beam Therapeutics; Jennifer R. Davis from Tempus AI; and Richard Person from Recursion. Together, they’ll discuss how organizations are leveraging #AI in #IP strategies, navigating rights issues, and preparing for future challenges in this transformative space. Explore the discussion on IP and generative AI: https://lnkd.in/erQ4QVaS #ProgrammingBiology | #RelentlesslyCurious

Thank you to Alex Philippidis and Genetic Engineering & Biotechnology News for naming us to their inaugural “A-list” in the article titled “Ten Companies to Watch in #AI Drug Discovery.” This recognition highlights how we’re redefining what’s possible in #MolecularDesign and therapeutic development—creating better medicines, faster. The article highlights our $1 billion collaboration with Novartis to develop protein therapeutics for multiple disease areas and our expanded collaboration with Amgen to advance monoclonal and bispecific antibodies. These milestones, alongside our clinical progress and recognition on the 2024 CNBC Disruptors list, demonstrate how we’re overcoming barriers that have long constrained drug discovery. Learn more about what sets us apart: https://lnkd.in/ene2qWTy #GenerativeAI | #ProteinEngineering

For the second year in a row, Sean Martin, our Chief Legal Officer & General Counsel, has been named to the GC Magazine & GC Powerlist. Compiled by The Legal 500, this prestigious list recognizes the most influential and innovative in-house legal leaders across industries. Sean’s recognition highlights his pivotal role in securing key patents, navigating the evolving #AI regulatory landscape, and forging impactful collaborations with partners like Novartis and MD Anderson Cancer Center. His leadership ensures Generate remains at the forefront of AI-driven drug development while safeguarding our mission. Learn more about Sean's honor: https://lnkd.in/gCNc_wcX #AudaciouslyAmbitious | #RelentlesslyCurious